Interestingly, immunotherapy was also a therapeutic option in RET-driven NSCLC patients at any line of treatment, with immune checkpoint inhibitor (ICI) combinations being more common in 1L and ICI monotherapy more common in 2/3L. This evidence concerns the gene RET and non-small cell lung carcinoma.